½ðɳjs55µÇ½

µ±Ç°Î»Öãº ÍøÕ¾Ê×Ò³ > ÐÂÎŶ¯Ì¬ > ÕýÎÄ

ÐÂÎŶ¯Ì¬
ÐÂÎŶ¯Ì¬
ҽѧ²¿½üÆÚÖØµã¿ÆÑÐËÙÀÀ
À´Ô´£º¡°ÈÊÐÄ¡±Í¨Ñ¶Éç¡¡µÚÒ»¸½ÊôÒ½½ðɳjs55µÇ½¡¡»ù´¡Ò½½ðɳjs55µÇ½¡¡Ò©½ðɳjs55µÇ½    ÈÕÆÚ£º2024-06-04     ä¯ÀÀ´ÎÊý£º
¡¡¡¡½üÆÚ£¬½ðɳjs55µÇ½ȡµÃ¶àÏî¿ÆÑÐÐÂÍ»ÆÆ£¬Ë¶¹ûÀÛÀÛ£¬³É¾ÍÆÄ·á¡£ÌØÑ¡²¿·ÖÖØµã¿ÆÑгɹûËÙÀÀ»Ø¹Ë¡£
Î÷°²½»Í¨´óѧҽ¹¤Ð­×÷ÍŶÓÔÚÈ«ÉíÂé×íÒ©Îï¼õ¶¾ÔöЧ·½ÃæÈ¡µÃÖØÒª½øÕ¹
¡¡
¡¡¡¡½üÈÕ£¬Î÷°²½»Í¨´ó½ðɳjs55µÇ½Ãü¿ÆÑ§Óë¼¼Êõ½ðɳjs55µÇ½²©Ê¿ÉúÕÅ˸ΪµÚÒ»×÷Õߣ¬ÉúÃü¿ÆÑ§Óë¼¼Êõ½ðɳjs55µÇ½ÎâµÀ³Î½ÌÊں͵ÚÒ»¸½ÊôÒ½½ðɳjs55µÇ½Âé×íÊÖÊõ²¿¸±Ö÷ÈθßΡ¸±Ö÷ÈÎҽʦΪ¹²Í¬Í¨Ñ¶×÷Õߣ¬ÔÚÖøÃûÆÚ¿¯¡¶¾Û¼¯Ìå¡·£¨Aggregate, IF=18.8£©ÉÏÔÚÏß·¢±íÒÔÌâΪ¡¶³¬ÉùÁªºÏѪÄÔÆÁÕϰÐÏò·Ö×ÓµÝËÍËĺÏÒ»·Ö×Ó¾Û¼¯ÌåÈëÄÔͨ¹ýÒì±û·Ó-ÒÀÍÐßäõ¥Ð­Í¬ÒÖÖÆGABAÊÜÌåÀ´ÔöÇ¿Âé×íЧ¹û²¢½µµÍ¶¾ÐÔ¡·µÄÑо¿ÂÛÎÄ¡£¸Ã¹¤×÷µÃµ½Á˽ðɳjs55µÇ½×ÔÈ»¿ÆÑ§»ù½ð¡¢ÉÂÎ÷Ê¡¡°¸ß²ã´ÎÈ˲ÅרÏîÖ§³Ö¼Æ»®¡±ÇàÄê°Î¼âÈ˲ÅÏîÄ¿µÄ×ÊÖú¡£Î÷°²½»Í¨´óѧ·ÖÎö²âÊÔÖÐÐĺÍÉúÎïҽѧʵÑéÖÐÐÄΪ±¾¹¤×÷ÌṩÁË´óÁ¿Ñо¿Ö§³Ö¡£
µÚÒ»¸½ÊôÒ½½ðɳjs55µÇ½ºÎÍúæç¿ÆÑÐÍŶÓÔÚÖ×ÁöÃâÒßÖÎÁÆÎ¢µ°°×Ò©ÎïÉè¼Æ·½Ãæ±³¿¿±³·¢±íÑо¿³É¹û
¡¡¡¡Î÷°²½»Í¨´óѧµÚÒ»¸½ÊôÒ½½ðɳjs55µÇ½ºÎÍúæçÑо¿Ô±ÎªÎÄÕÂͨѶ×÷Õߣ¬Ö×ÁöÄڿƽ¯°®Ãñ²©Ê¿Îª±¾ÎĵÚÒ»×÷Õߣ¬ÔÚÖøÃûÆÚ¿¯¡¶ACS Nano¡·£¨IF=17.1£©ÉÏ·¢±íÌâΪ¡°Advancing the boundaries of immunotherapy in lung adenocarcinoma with idiopathic pulmonary fibrosis by a biomimetic proteinoid enabling selective endocytosis¡±µÄ¿ÆÑÐÂÛÎÄ¡£
µÚÒ»¸½ÊôÒ½½ðɳjs55µÇ½Ö×Áö·ÅÁÆ¿ÆÕÔ¶«Àû½ÌÊÚÍŶÓÔÚ¡¶ÁøÒ¶µ¶¡·Õý¿¯·¢±íÖØÒªÑо¿ÆÀÊöÎÄÕÂ
¡¡¡¡µÚÒ»×÷ÕßÕÔ¶«Àû½ÌÊÚ¡¢Í¨Ñ¶×÷Õß·ӽ¿­ÎïÀíʦ£¨¹²Í¬×÷ÕßÀîÒã¸ß¼¶¹¤³Ìʦ¡¢ÇúÒÔÆ½Ö÷ÖÎҽʦºÍºÎ³¿è¡Ö÷ÖÎҽʦ£©ÔÚ¡¶ÁøÒ¶µ¶¡·£¨IF=168.9£©ÉϵÄcorrespondenceרÀ¸ÉÏ·¢±íÒÔ¡°Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial£¨SIBÈéÏÙ·ÅÉäÖÎÁÆÃæÁÙµÄÌôÕ½£ºIMPORT HIGHÊÔÑ飩¡±ÎªÌâµÄÎÄÕ¡£
»ù´¡Ò½½ðɳjs55µÇ½ÍŶÓÑо¿·¢±íÖáÍ»ÄÒÅÝɸѡлúÖÆ
¡¡¡¡Î÷°²½»Í¨´óѧ»ù´¡Ò½½ðɳjs55µÇ½ÑîÌÊÚ£¬ÍŶӳÉÔ±²©Ê¿ºóº«ÔÀ¡¢ÁõÕÜ£¬²©Ê¿ÉúÀîÃô£¬Ñо¿ÉúÕÔ±ùÇå¡¢ÁõÑà¡¢Íõ»Û³¬£¬ÔÚ¡¶ÃÀ¹ú¿Æ½ðɳjs55µÇ½½ðɳjs55µÇ½¿¯¡·(PNAS)ÉÏ·¢±íÌâΪ¡¶MARK2Á×ËữKIF13AµÄ14-3-3½áºÏλµãµ÷¿Ø×ªÌúµ°°×ÊÜÌåÄÒÅÝÔÚÊ÷Í»Éϵļ«»¯×ªÔË¡·£¨MARK2 phosphorylates KIF13A at a 14-3-3 binding site to polarize vesicular transport of transferrin receptor within dendrites£©µÄ¿ÆÑÐÎÄÕ¡£¸ÃÑо¿ÎªÖáÍ»ÎïÖʵÄÑ¡ÔñÐÔתÔËÌṩÁËÒ»¸öеÄÊӽǣ¬¼´ÄÒÅݵļ«ÐÔתÔË¿ÉÄÜÓëÖáÍ»ÆðÊ¼ÇøÓò¸»¼¯µÄµ°°×¼¤Ã¸µ÷¿ØÏà¹Ø¡£
Ò©½ðɳjs55µÇ½ÕÅÑåÃñ½ÌÊÚÁªºÏ»¯¹¤½ðɳjs55µÇ½³ÂöνÌÊÚ¡¢Äܶ¯½ðɳjs55µÇ½Áõº£ºþ½ÌÊÚ
¹¹½¨»ùÓÚÉúÀíÏìÓ¦¼°µ÷¿ØÐÍÄÉÃ×½ð´ØµÄ¾«×¼¿ÉÊÓ¶ñÐÔÖ×ÁöÖÎÁÆ
¡¡¡¡Î÷°²½»Í¨´óѧҩ½ðɳjs55µÇ½ÕÅÑåÃñ½ÌÊÚ¡¢»¯¹¤½ðɳjs55µÇ½³ÂöνÌÊÚ¡¢Äܶ¯½ðɳjs55µÇ½Áõº£ºþ½ÌÊÚΪÂÛÎĵÄͨѶ×÷Õߣ¬²©Ê¿ÉúÁõ·ã¡¢ÑîÌì·ãºÍ³£Ð¡ÎÀΪ¹²Í¬µÚÒ»×÷Õߣ¬ÔÚ¡¶½ðɳjs55µÇ½¿ÆÑ§ÆÀÂÛ¡·£¨National Science Review£©·¢±íÌâΪ¡°Intelligent gold nanocluster for effective treatment of malignant tumor via tumor-specific photothermal-chemodynamic therapy with AIE guidance¡±µÄ¿ÆÑÐÂÛÎÄ¡£¸ÃÂÛÎĵõ½Á˽ðɳjs55µÇ½¸ß²ã´ÎÈ˲ÅÌØÊâÖ§³Ö¼Æ»®¡¢½ðɳjs55µÇ½×ÔÈ»¿ÆÑ§»ù½ð¡¢ÉÂÎ÷Ê¡×ÔÈ»¿ÆÑ§»ù½ð¡¢Î÷°²½»Í¨´óѧ¡°ÇàÄê°Î¼âÈ˲ÅÖ§³Ö¼Æ»®¡±µÈÏîÄ¿µÄ´óÁ¦Ö§³Ö¡£
  • ½»´óÖ÷Ò³
  • ѧ²¿ÐÅÏä
  • ˼ԴBBS
  • ͼÊé¹Ý
  • ˼ԴÓʼþ
  • ÐÅÏ¢ÃÅ»§
  • ½ÌʦÖ÷Ò³

µØÖ·£ºÉÂÎ÷Ê¡Î÷°²ÊÐÑãËþÎ÷·76ºÅ£¬Óʱࣺ710061

°æÈ¨ËùÓУº½ðɳjs55µÇ½

·ÃÎÊÁ¿£º

΢ÐÅÆ½Ì¨

½ðɳjs55µÇ¼Èë¿Ú-½ðɳjs55µÇ¼Èë¿Ú×îаæ2025ÏÂÔØV10.23...